Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Download Publication
28 Jan 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

2 Feb 2024

Systemic Nasal Drug Delivery for CNS Diseases and Beyond

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
30 Jan 2024

Nanoparticle Formulation Strategies for Intranasal Drug Delivery

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
3 Jan 2024

Feasibility of Intranasal Delivery of Thin-Film Freeze-Dried Monoclonal Antibodies

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
18 Dec 2023

Elevating Medication Adherence and Clinical Outcomes with Connected Drug Delivery

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
1 2 3 4 5 25
Back To Top